TECHNICAL SERVICES AGREEMENTTechnical Services Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This Technical Services Agreement (“Agreement”) is made and entered into as of the 6 day of October, 2018 (“Effective Date”) by and between Hangzhou Just Biotherapeutics Co., Ltd., a limited liability company having offices at 11/F, Building 5, No.2 Ke Ji Yuan Road, Hangzhou Eco-Tech Development Area, Hangzhou, China, 310018 (“Just”) and Inhibrx, Inc. (“Inhibrx”), a Delaware corporation with an address at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037. Just and Inhibrx may be referred to herein each, individually, as a “Party” or, collectively, as the “Parties”.
FIRST AMENDMENT, WAIVER AND CONSENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS FIRST AMENDMENT, WAIVER AND CONSENT to the Loan and Security Agreement (this “Amendment”) is entered into as of August 15, 2016 (the “First Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and ”), and Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 1
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (“Agreement”) is made and entered into as of the 28th day of February 2018, Pacific Standard time (the “Effective Date”) by and between Elpiscience Biopharmaceuticals, Inc., a Cayman Islands company having offices at Offices of Corporate Filing Services Ltd., 3rd Floor, Harbour Centre, George Town, P.O. Box 613, Grand Cayman KY1-1107, Cayman Islands (“Elpiscience”) and Inbrx105 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Elpiscience and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (“Agreement”) is made and entered into as of the 21st day of June 2017, New York Time (the “Effective Date”) by and between Hangzhou Just Biotherapeutics Co., Ltd., a limited liability company having offices at 11/F, Building 5, No.2 Ke Ji Yuan Road, Hangzhou Eco-Tech Development Area, Hangzhou, China, 310018 (“Just”) and Inbrx109 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Just and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED AMENDED AND RESTATED MASTER SERVICES AGREEMENTMaster Services Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Master Services Agreement (“Agreement”) is dated August 28, 2018 (the “Restated Effective Date”) and is between Inhibrx, Inc. (“Client”) and WuXi Biologics (Hong Kong) Limited (“Provider”).
CONFIDENTIAL TREATMENT REQUESTED License AgreementConfidential Treatment Requested • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (this “Agreement”), effective as of December 20, 2018 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENTLicense Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”) is made effective e as of July 1, 2013 (“Effective Date”) by and between INBRX 103, LLC, a limited liability company with an address at 11099 North Torrey Pines Road, Suite 130, La Jolla, CA 92037 (“Inhibrx”), and Celgene Corporation a Delaware corporation with an address at 86 Morris Avenue, Summit, NJ 07901 (“Licensee”). Inhibrx and Licensee each may be referred to herein individually as a “Party” and together as the “Parties.”
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • February 22nd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This Amendment (the “Amendment”) is effective on November 23, 2018 (“Amendment Date”), by and among INBRX 103, LLC, a limited liability company with an address at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Inhibrx”), Celgene Corporation, a Delaware corporation with an address at 86 Morris Avenue, Summit, NJ 07901 (“Licensee”) and Inhibrx, Inc. (formerly Inhibrx, LLC), a Delaware corporation with an address at 11099 North Torrey Pines Road, Suite 130, La Jolla, CA 92037 (“Parent”), and amends the License Agreement by and among Inhibrx and Licensee, dated July 1, 2013 (the “License Agreement”). Inhibrx, Parent and Licensee are referred to herein as the “Parties” and each as a “Party.” Capitalized terms not otherwise defined herein have the meanings specified in the License Agreement.
